Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06881992 · ClinicalTrials.gov registry record · Phase 3
A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism
A Phase 3 study of Tumor Hyperinsulinism (Tumor HI), sponsored by Rezolute.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 16
- Enrollment target
- 13
- Study locations
NCT06881992 is a Phase 3 study of Tumor Hyperinsulinism (Tumor HI) that is actively recruiting participants, run by Rezolute. The registered enrollment target is 16 participants. The trial reports 13 study locations across 13 states.
The verdict
NCT06881992, a Phase 3 study of Tumor Hyperinsulinism (Tumor HI), is actively recruiting participants, sponsored by Rezolute.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 16 participants
- Enrollment target
- 13
- Study locations
Study Summary
The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
Conditions Studied
Interventions
- DRUG Ersodetug
Study Locations (13)
Illinois
- Investigative Site - Chicago
Maryland
- Investigative Site - Bethesda
Massachusetts
- Investigative Site - Boston
Minnesota
- Investigative Site - Rochester
New York
- Investigative Site - New York
Ohio
- Investigative Site - Canton
Oregon
- Investigative Site - Portland
Texas
- Investigative Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-04-16 |
| Est. Completion | 2027-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06881992
The ClinicalTrials.gov registry entry for NCT06881992 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rezolute, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tumor Hyperinsulinism (Tumor HI) appearing as the primary indexed condition, and to 1 intervention - of which Ersodetug is the first listed.
NCT06881992 reports 13 study locations spanning 13 distinct geographic areas - top geographies include Illinois, Maryland, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06881992 about?
NCT06881992 is a clinical study titled "A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism". The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).
What is the current status of trial NCT06881992?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 16 participants. The study started on 2025-04-16. Estimated completion is 2027-09.
What conditions does trial NCT06881992 study?
This clinical trial studies the following conditions: Tumor Hyperinsulinism (Tumor HI).
What interventions are being tested in trial NCT06881992?
The interventions under investigation include: Ersodetug (DRUG).
Who is sponsoring clinical trial NCT06881992?
This trial is sponsored by Rezolute, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06881992 being conducted?
This trial has 13 study locations across Illinois, Maryland, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.